Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005, Annals of the Rheumatic Diseases, vol.67, issue.7, pp.960-966, 2000. ,
DOI : 10.1136/ard.2007.076232
Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008, Arthritis & Rheumatism, vol.16, issue.10, pp.3136-3177, 2007. ,
DOI : 10.1002/art.30520
Gout in the Maori, Ann Rheum Dis. juin, vol.19, pp.120-125, 1960. ,
Uric acid, gout and public health in the South Pacific, N Z Med J. mai, vol.65, issue.405, pp.295-300, 1966. ,
Gout is on the increase in New Zealand, Annals of the Rheumatic Diseases, vol.56, issue.1, pp.22-28, 1997. ,
DOI : 10.1136/ard.56.1.22
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population, J Rheumatol. août, vol.31, issue.8, pp.1582-1589, 2004. ,
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States, Arthritis & Rheumatism, vol.42, issue.5, pp.778-99, 1998. ,
DOI : 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V
Prevalence and incidence of the diagnosis of gout in Great Britain., Annals of the Rheumatic Diseases, vol.38, issue.2, pp.101-107, 1979. ,
DOI : 10.1136/ard.38.2.101
Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study, Annals of the Rheumatic Diseases, vol.20, issue.4, pp.661-668, 2015. ,
DOI : 10.1136/annrheumdis-2013-204463
Epidemiology of gout: is the incidence rising?, J Rheumatol. nov, vol.29, issue.11, pp.2403-2409, 2002. ,
Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.1728-1761, 2009. ,
DOI : 10.1136/ard.2008.096693
EULAR evidence based recommendations for gout. Part I: Diagnosis, Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) ,
Mechanisms of gout inflammation]. Presse Médicale Paris Fr 1983, sept, vol.40, issue.9, pp.836-879, 2011. ,
Engagement of fatty acids with toll-like receptor 2 drives interleukin-1?? production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis, Arthritis & Rheumatism, vol.96, issue.11, pp.3237-3285, 2010. ,
DOI : 10.1002/art.27667
Mechanisms of inflammation in gout, Rheumatology, vol.44, issue.9, pp.1090-1096, 2005. ,
DOI : 10.1093/rheumatology/keh640
Recent developments in crystal-induced inflammation pathogenesis and management, Current Rheumatology Reports, vol.111, issue.3, pp.243-50, 2007. ,
DOI : 10.1007/s11926-007-0039-5
Inhibition and prevention of monosodium urate monohydrate crystal???induced acute inflammation in vivo by transforming growth factor ??1, Arthritis & Rheumatism, vol.150, issue.7, pp.1192-1200, 1996. ,
DOI : 10.1002/art.1780390718
Monosodium urate crystals in inflammation and immunity, Immunological Reviews, vol.101, issue.Suppl, pp.203-220, 2010. ,
DOI : 10.1111/j.0105-2896.2009.00851.x
The inflammasome, autoinflammatory diseases, and gout, Joint Bone Spine, vol.74, issue.6, pp.571-577, 2007. ,
DOI : 10.1016/j.jbspin.2007.04.004
Mechanisms of uric acid crystal-mediated autoinflammation, Immunological Reviews, vol.172, issue.Suppl 1, pp.218-250, 2010. ,
DOI : 10.1111/j.0105-2896.2009.00860.x
Cellular characterization of the gouty tophus: A quantitative analysis, Arthritis & Rheumatism, vol.10, issue.Suppl, pp.1549-56, 2010. ,
DOI : 10.1002/art.27356
Enhanced osteoclastogenesis in patients with tophaceous gout: Urate crystals promote osteoclast development through interactions with stromal cells, Arthritis & Rheumatism, vol.168, issue.6, pp.1854-65, 2008. ,
DOI : 10.1002/art.23488
Inflammatory Microcrystals Alter the Functional Phenotype of Human Osteoblast-Like Cells In Vitro: Synergism with IL-1 to Overexpress Cyclooxygenase-2, The Journal of Immunology, vol.168, issue.10, pp.5310-5317, 1950. ,
DOI : 10.4049/jimmunol.168.10.5310
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT), Annals of the Rheumatic Diseases, vol.65, issue.10, pp.1312-1336, 2006. ,
DOI : 10.1136/ard.2006.055269
Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen, J Rheumatol. avr, vol.27, issue.4, pp.1045-50, 2000. ,
Asymptomatic hyperuricemia. Risks and consequences in the normative aging study, The American Journal of Medicine, vol.82, issue.3, pp.421-427, 1987. ,
DOI : 10.1016/0002-9343(87)90441-4
Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort, Arthritis & Rheumatism, vol.157, issue.Suppl, pp.1069-76, 2010. ,
DOI : 10.1002/art.27338
Uric acid excretion in the relatives of patients with gout., Annals of the Rheumatic Diseases, vol.29, issue.4, pp.397-400, 1970. ,
DOI : 10.1136/ard.29.4.397
Genetic control of the renal clearance of urate: a study of twins., Annals of the Rheumatic Diseases, vol.51, issue.3, pp.375-382, 1992. ,
DOI : 10.1136/ard.51.3.375
Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population, Arthritis & Rheumatism, vol.279, issue.1, pp.292-300, 2006. ,
DOI : 10.1002/art.21499
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study, The Lancet, vol.372, issue.9654, pp.1953-61, 2008. ,
DOI : 10.1016/S0140-6736(08)61343-4
Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in Men, Archives of Internal Medicine, vol.165, issue.7, pp.742-750, 2005. ,
DOI : 10.1001/archinte.165.7.742
Epidemiology of Gout, Rheumatic Disease Clinics of North America, vol.40, issue.2, p.223, 2010. ,
DOI : 10.1016/j.rdc.2014.01.001
Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey, Arthritis & Rheumatism, vol.363, issue.1, pp.109-124, 2007. ,
DOI : 10.1002/art.22466
Gout, The Lancet, vol.375, issue.9711, pp.318-346, 2010. ,
DOI : 10.1016/S0140-6736(09)60883-7
URL : https://hal.archives-ouvertes.fr/hal-01187430
POLYARTICULAR GOUT, The Lancet, vol.333, issue.8647, p.1142, 1989. ,
DOI : 10.1016/S0140-6736(89)92422-7
2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia, Arthritis Care & Research, vol.59, issue.10, pp.1431-1477, 2012. ,
DOI : 10.1002/acr.21772
2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis, Arthritis Care & Research, vol.64, issue.Suppl, pp.1447-61, 2012. ,
DOI : 10.1002/acr.21773
Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial, The Lancet, vol.371, issue.9627, pp.1854-60, 2008. ,
DOI : 10.1016/S0140-6736(08)60799-0
COX-2 Selective Inhibitors in the Treatment of Osteoarthritis, Seminars in Arthritis and Rheumatism, vol.38, issue.3, pp.165-87, 2008. ,
DOI : 10.1016/j.semarthrit.2007.10.004
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout, Rheumatology, vol.46, issue.8, pp.1372-1376, 2007. ,
DOI : 10.1093/rheumatology/kem056a
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial, Arthritis & Rheumatism, vol.63, issue.Suppl 1, pp.598-606, 2004. ,
DOI : 10.1002/art.20007
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout, Rheumatology, vol.46, issue.7, pp.1126-1158, 2007. ,
DOI : 10.1093/rheumatology/kem090
Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial, The Journal of Rheumatology, vol.39, issue.9, pp.1859-66, 2012. ,
DOI : 10.3899/jrheum.110916
Colchicine for acute gout, Cochrane Database Syst Rev, vol.14, issue.12, p.6190, 2006. ,
DOI : 10.1002/14651858.CD006190
Colchicine Update: 2008, Seminars in Arthritis and Rheumatism, vol.38, issue.6, pp.411-420, 2008. ,
DOI : 10.1016/j.semarthrit.2008.08.006
Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation, Current Rheumatology Reports, vol.21, issue.Suppl1, pp.218-245, 2008. ,
DOI : 10.1007/s11926-008-0036-3
Systemic corticosteroids for acute gout, Cochrane Database Syst Rev, vol.8, issue.3, p.5521, 2008. ,
DOI : 10.1002/14651858.CD005521.pub2
Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?, Nature Clinical Practice Rheumatology, vol.295, issue.1, pp.12-15, 2009. ,
DOI : 10.1038/ncprheum0962
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study, Annals of the Rheumatic Diseases, vol.70, issue.7, pp.1264-71, 2011. ,
DOI : 10.1136/ard.2010.144063
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study, Arthritis Care & Research, vol.64, issue.Suppl 3, pp.1462-70, 2012. ,
DOI : 10.1002/acr.21690
Gout, JAMA, vol.289, issue.21, pp.2857-60, 2003. ,
DOI : 10.1001/jama.289.21.2857
Gesamtpuringehalt in ausgew??hlten Lebensmitteln, Zeitschrift f??r Ern??hrungswissenschaft, vol.41, issue.4, pp.205-218, 1987. ,
DOI : 10.1007/BF02023808
Effects of food, fast and alcohol on serum uric acid and acute attacks of gout, The American Journal of Medicine, vol.42, issue.1, pp.38-57, 1967. ,
DOI : 10.1016/0002-9343(67)90005-8
A controlled study of diet in patients with gout Effect of weight-loss on plasma and urinary levels of uric acid, Ann Rheum Dis. avr, vol.422, issue.27789, pp.1223-1227, 1972. ,
Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study, Annals of the Rheumatic Diseases, vol.59, issue.7, pp.3-36, 2000. ,
DOI : 10.1136/ard.59.7.539
Allopurinol-induced DRESS syndrome, Isr Med Assoc J IMAJ. oct, vol.7, issue.10, pp.656-60, 2005. ,
Clinical heterogeneity of drug hypersensitivity, Toxicology, vol.209, issue.2, pp.123-132, 2005. ,
DOI : 10.1016/j.tox.2004.12.022
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout, Annals of the Rheumatic Diseases, vol.57, issue.9, pp.545-554, 1998. ,
DOI : 10.1136/ard.57.9.545
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial, Arthritis & Rheumatism, vol.45, issue.11, pp.1540-1548, 2008. ,
DOI : 10.1002/art.24209
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout, New England Journal of Medicine, vol.353, issue.23, pp.2450-61, 2005. ,
DOI : 10.1056/NEJMoa050373
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial, Arthritis Research & Therapy, vol.12, issue.2, p.63, 2010. ,
DOI : 10.1186/ar2978
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout, Arthritis & Rheumatism, vol.50, issue.3, pp.1021-1029, 2007. ,
DOI : 10.1002/art.22403
PEG-uricase in the management of treatment-resistant gout and hyperuricemia, Advanced Drug Delivery Reviews, vol.60, issue.1, pp.59-68, 2008. ,
DOI : 10.1016/j.addr.2007.06.011
Pegloticase, Nature Reviews Drug Discovery, vol.348, issue.1, pp.17-25, 2011. ,
DOI : 10.1038/nrd3349
New Therapies for Gout, Annual Review of Medicine, vol.64, issue.1, pp.325-362, 2013. ,
DOI : 10.1146/annurev-med-080911-105830
Epidemiology of gout: is the incidence rising?, J Rheumatol. nov, vol.29, issue.11, pp.2403-2409, 2002. ,
Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice, BMC Family Practice, vol.60, issue.572, p.170, 2013. ,
DOI : 10.3399/bjgp10X483562
Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial, Annals of Emergency Medicine, vol.49, issue.5, pp.670-677, 2007. ,
DOI : 10.1016/j.annemergmed.2006.11.014
Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study, J Rheumatol. sept, vol.15, issue.9, pp.1422-1428, 1988. ,
Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol, Arthritis Rheum. avr Arthritis Rheum. août, vol.2264, issue.48, pp.2529-2565, 1979. ,
The allopurinol hypersensitivity syndrome, Journal of the American Academy of Dermatology, vol.1, issue.4, pp.365-74, 1979. ,
DOI : 10.1016/S0190-9622(79)70031-4
Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Troms?? study, Nutrition Journal, vol.24, issue.283, p.49, 2015. ,
DOI : 10.1093/ajcp/54.1.118
Patients??? knowledge and beliefs concerning gout and its treatment: a population based study, BMC Musculoskeletal Disorders, vol.72, issue.3, p.180, 2012. ,
DOI : 10.1136/ard.2007.070755